Third-Party Tested ≥98% HPLC Purity — USA Shipped

GH Secretagogues Research Guide

CJC-1295 (with DAC): Mechanism, Handling & Research Guide

Also known as: CJC-1295 DAC, GRF 1-29 + Drug Affinity Complex

Key Facts

CJC-1295 (with DAC) is a gh secretagogues research peptide (C152H252N44O42, MW 3367.95 g/mol). Extended half-life GHRH analogue with Drug Affinity Complex for sustained GH research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification Long-acting GHRH analog with Drug Affinity Complex
Molecular Formula C152H252N44O42
Molecular Weight 3367.95 g/mol
Research Half-Life ~6–8 days (the DAC binds albumin, extending circulation)
Form Lyophilized powder
Research Category GH Secretagogues

What is CJC-1295 (with DAC)?

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue conjugated with a maleimidopropionic acid (MPA) linker that binds covalently to serum albumin after entering circulation. This albumin conjugation dramatically extends the peptide's half-life from approximately 30 minutes to 6-8 days, enabling sustained elevation of growth hormone levels from a single use. The mechanism involves the same GHRH receptor activation as the non-DAC version, but the prolonged pharmacokinetic profile produces continuous rather than pulsatile GH stimulation. In a pivotal pharmacokinetic study, Teichman et al. Compared to CJC-1295 without DAC, the DAC version is suited for research studies requiring prolonged GH axis stimulation, while the non-DAC form better models physiological pulse dynamics. Research also suggests potential applications in lean mass preservation, bone mineral density, and sleep quality improvement through sustained GH pathway activation. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This compound is studied by endocrinology research programs, pharmacokinetics laboratories, and institutions investigating sustained-release peptide delivery strategies.

CJC-1295 (with DAC) Research Applications

In published and preclinical research, CJC-1295 (with DAC) has been studied across the following areas:

  • Sustained GH secretion studies
  • Lean mass and fat metabolism
  • Bone health research
  • Sleep regulation through GH pathways

CJC-1295 (with DAC) in Research: Study Context

The DAC (Drug Affinity Complex) variant of CJC-1295 incorporates a maleimido group that binds covalently to serum albumin, extending half-life from minutes to several days. It is studied for sustained GH/IGF-1 elevation profiles. Reconstitute with bacteriostatic water for laboratory use only.

How CJC-1295 (with DAC) Compares

Researchers frequently evaluate CJC-1295 (with DAC) alongside related compounds:

CJC-1295 (with DAC) — Frequently Asked Questions

Is CJC-1295 (with DAC) legal to buy for research?
CJC-1295 (with DAC) is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does CJC-1295 (with DAC) come with a Certificate of Analysis?
Yes. Every batch of CJC-1295 (with DAC) from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is CJC-1295 (with DAC) and how does it work?
CJC-1295 with DAC is a modified GHRH analogue featuring a Drug Affinity Complex — a maleimide derivative of lysine that covalently binds to serum albumin after entering circulation. This albumin binding extends the peptide's half-life from minutes to 6-8 days, enabling sustained stimulation of pituitary GH release through continuous GHRH receptor activation. This produces elevated GH and IGF-1 levels over an extended period in research models.
What research has been done on CJC-1295 (with DAC)?
Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that a single use of CJC-1295 with DAC elevated GH levels for 6+ days and IGF-1 levels for 9-11 days in human subjects. Phase 2 studies showed concentration-dependent increases in both GH and IGF-1 with good tolerability. Preclinical research has explored its effects on body composition, sleep architecture (through GH-mediated slow-wave sleep), and bone density.
How does CJC-1295 with DAC compare to Tesamorelin?
Both are GHRH analogues, but they differ significantly in pharmacokinetics. CJC-1295 with DAC provides sustained GH elevation over 6-8 days due to albumin binding, while tesamorelin has a shorter duration requiring daily use. Tesamorelin has FDA approval for HIV lipodystrophy and more extensive clinical trial data. CJC-1295 with DAC is more commonly used in research studying prolonged GH exposure effects.
All research guides